NCT01448447 - Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions

Breast CancerDuctal Carcinoma in Situ

Interventions

DEVICE

Mammosite ML

34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days

DEVICE

Mammosite ML

5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)

Trial Locations (2)

63011

Mercy Clinic St. Louis Cancer and Breast Institute, St Louis

63141

Mercy Hospital St. Louis, St Louis